Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: An overview of the literature

Rheumatology

Volumn 51, Issue 2, 2012, Pages 216-229

  Verstappen, Suzanne M M ^a   Fautrel, Bruno ^b   Dadoun, Sabrina ^b   Symmons, Deborah P M ^a   Boonen, Annelies ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biologic therapies; Employment; Methods; Overview.; Productivity loss

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ABSENTEEISM; ANKYLOSING SPONDYLITIS; ARTHRITIS; BIOLOGICAL THERAPY; HUMAN; PRIORITY JOURNAL; PRODUCTIVITY; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; UNEMPLOYMENT;

ARTHRITIS; BIOLOGICAL AGENTS; EFFICIENCY; EMPLOYMENT; EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS;

EID: 84856105416     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker363     Document Type: Review

References (56)

1. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354: 1932-39.
2. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
3. Weinblatt ME, Keystone EC, Furst DE et al. A fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
4. Kavanaugh A, Antoni C, Krueger GG et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65: 471-77.
5. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64: 1150-7.
6. Baraliakos X, Brandt J, Listing J et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63.
7. Haibel H, Rudwaleit M, Brandt HC et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54: 678-81.
8. Raterman HG, Hoving JL, Nurmohamed MT et al. Work ability: a new outcome measure in rheumatoid arthritis? Scand J Rheumatol 2010;39:127-31.
9. Herenius MM, Hoving JL, Sluiter JK et al. Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab. J Occup Environ Med 2010;52:618-21.
10. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31:849-55.
11. Kavanaugh A, Smolen JS, Emery P et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009;61: 1592-600.
12. Anis A, Zhang W, Emery P et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology 2009;48:1283-9.
13. Kimel M, Cifaldi M, Chen N et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008;35:206-15.
14. Smolen JS, Han C, van der Heijde D et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
15. van Vollenhoven RF, Cifaldi MA, Ray S et al. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res 2010; 62:226-34.
16. Cole JC, Li T, Lin P et al. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. Rheumatology 2008;47:1044-50.
17. Yelin E, Trupin L, Katz P et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:3046-54.
18. Bejarano V, Quinn M, Conaghan PG et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
19. Hoving JL, Bartelds GM, Sluiter JK et al. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol 2009;38: 246-50.
20. Zhang W, Bansback N, Guh D et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 2008;35:1729-36.
21. Mittendorf T, Dietz B, Sterz R et al. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology 2008;47:188-93.
22. Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009;68:930-37.
23. Olofsson T, Englund M, Saxne T et al. Decrease in sick leave among patients with rheumatoid arthritis in the first months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study. Ann Rheum Dis 2010;69:2131-6.
24. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
25. Neovius M, Simard JF, Klareskog L et al. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis 2011;70:1407-14.
26. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2211-7.
27. Allaire S, Wolfe F, Niu J et al. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008;59:1082-9.
28. Farahani P, Levine M, Gaebel K et al. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol 2006;33:665-70.
29. Augustsson J, Neovius M, Cullinane-Carli C et al. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 2010;69:126-31.
30. van der Heijde D, Han C, DeVlam K et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55:569-74.
31. Barkham N, Coates LC, Keen H et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010;69:1926-8.
32. Listing J, Brandt J, Rudwaleit M et al. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63:1670-2.
33. Maksymowych WP, Gooch KL, Wong RL et al. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 2010;37:385-92.
34. Keat AC, Gaffney K, Gilbert AK et al. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology 2008; 47:481-3.
35. Cheung PP, Tymms KE, Wilson BJ et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 2008;38:396-401.
36. Kimball AB, Bensimon AG, Guerin A et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebocontrolled, phase III trial. Am J Clin Dermatol 2011;12: 51-62.
37. Kimball AB, Jackson JM, Sobell JM et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. J Drugs Dermatol 2007;6:299-306.
38. Kavanaugh A, Antoni C, Mease P et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-59.
39. Verstappen SM, Watson KD, Lunt M et al. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49: 1570-7.
40. Aletaha D, Strand V, Smolen JS et al. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.
41. Han C, Smolen J, Kavanaugh A et al. Comparison of employability outcomes among patients with early or longstanding rheumatoid arthritis. Arthritis Rheum 2008;59: 510-4.
42. Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004;63:221-5.
43. Verstappen SM, Bijlsma JW, Verkleij H et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
44. Melin R, Fugl-Meyer AR. On prediction of vocational rehabilitation outcome at a Swedish employability institute. J Rehabil Med 2003;35:284-9.
45. Mattke S, Balakrishnan A, Bergamo G et al. A review of methods to measure health-related productivity loss. Am J Manag Care 2007;13:211-7.
46. Gilworth G, Chamberlain MA, Harvey A et al. Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum 2003;49:349-54.
47. Beaton DE, Tang K, Gignac MA et al. Reliability, validity, and responsiveness of five at-work productivity measures in patients with rheumatoid arthritis or osteoarthritis. Arthritis Care Res 2010;62:28-37.
48. Escorpizo R, Bombardier C, Boonen A et al. Worker productivity outcome measures in arthritis. J Rheumatol 2007;34:1372-80.
49. Revicki DA, Irwin D, Reblando J et al. The accuracy of self-reported disability days. Med Care 1994;32: 401-4.
50. Gignac MA, Cao X, Lacaille D et al. Arthritis-related work transitions: a prospective analysis of reported productivity losses, work changes, and leaving the labor force. Arthritis Rheum 2008;59:1805-13.
51. Klein-Geltink JE, Rochon PA, Dyer S et al. Readers should systematically assess methods used to identify, measure and analyze confounding in observational cohort studies. J Clin Epidemiol 2007;60:766-72.
52. World Health Organization. International Classification of Functioning, Disability, and Health: ICF. Geneva: World Health Organization (WHO), 2001.
53. Sokka T, Kautiainen H, Pincus T et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12:R42.
54. Karasek R, Brisson C, Kawakami N et alThe Job Content Questionnaire (JCQ): an instrument for internationally comparative assessments of psychosocial job characteristics. J Occup Health Psychol 1998;3: 322-55.
55. Siegrist J, Peter R, Junge A et alLow status control, high effort at work and ischemic heart disease: prospective evidence from blue-collar men. Soc Sci Med 1990;31: 1127-34.
56. Haibel H, Song IH, Rudwaleit M et alMulticenter openlabel study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. Clin Exp Rheumatol 2008; 26:247-52.